Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 301-305

  Saarto, T ^a   Blomqvist, C ^a   Rissanen, P ^a   Auvinen, A ^b   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b STUK RADIATION AND NUCLEAR SAFETY AUTHORITY   (Finland)

Author keywords

Adjuvant chemotherapy; Breast cancer; Dose intensity; Haematological toxicity; Total dose

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIESTROGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; PYRIMIDINE ANTAGONIST; TAMOXIFEN; TEGAFUR;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031031616     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.49     Document Type: Article

References (35)

1. Ahmann DL, O'Fallon JR, Scanlon PW, Payne WS, Bisel HF, Edmonson JH, Frytak S, Hahn RG, Ingle JN, Rubin J and Creagan ET (1982) A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 5: 371-381
2. Ang PT, Buzdar AU, Smith TL, Kau S and Hortobagyi GN (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7: 1677-1684
3. Blomqvist C, Tiusanen K, Elomaa I, Rissanen P, Hietanen T, Heinonen E and Grohn P (1992) The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. Br J Cancer 66: 1171-1176
4. Bonadonna G and Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 34: 10-15
5. Carmo-Pereira J, Costa FO, Henriques E, Godinho F, Cantinho LM, Sales LA and Rubens RD (1987) A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471-473
6. Cox DR (1972) Regression models and life-tables. JR Statist Soc Ser B 34: 187-220
7. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER and Deutsch M (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496
8. Fumoleau P, Devaux Y, Vo Van ML, Kerbrat P, Fargeot P, Schraub S, Mihura J, Namer M and Mercier M (1993) Premenopausal patients with node-positive resectable breast cancer: preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. Drugs 45: 38-45
9. Geller NL, Hakes TB, Petroni GR, Currie V and Kaufman R (1990) Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer 66: 1678-1684
10. Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad Emn, Costanzi J, Hoogstraten B, Athens J, Maloney T, Mccracken J and Vaughn C (1982) Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer 50: 423-434
11. Henderson IC, Gelman RS, Harris JR and Canellos GP (1986) Duration of therapy in adjuvant chemotherapy trials. Natl Cancer Inst Monogr 1: 95-98
12. Henderson IC, Hayes DF and Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501-1515
13. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY and Rodriguez V (1987a) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354-364
14. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY and Blumenschein GR (1987b) High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5: 178-184
15. Howell A, Rubens RD, Bush H, George WD, Howat JM, Crowther D, Sellwood RA, Hayward JL, Knight RK, Bulbrook RD, Fentiman IS and Chaudary M (1984) A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Recent Results Cancer Res 96: 74-89
16. Hryniuk W and Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288
17. Hryniuk W and Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162-1170
18. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
19. Longo DL, Duffey PL, Devita VJ, Wesley MN, Hubbard SM and Young RC (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9: 2042-2051
20. Ludwig Breast Cancer Study Group (1985) A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45: 4454-4459
21. Mouridsen HT, Rose C, Brincker H, Thorpe SM, Rank F, Fischerman K and Andersen KW (1984) Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res 96: 117-128
22. Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Sertoli MR and Rosso R (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12: 481-485
23. Redmond C, Fisher B and Wieand HS (1983) The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 67: 519-526
24. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU and Blumenschein GR (1981) Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 48: 227-232
25. Saarto T, Blomqvist C, Tiusanen K, Gröhn P, Rissanen P and Elomaa I (1995) The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. Eur J Surg Oncol 21: 146-150
26. Samonigg H, Stoger H, Kasparek AK, Schmid M, Dusleag J, Pfeiffer K, Smola M, Steindorfer P and Lechner, P (1991) Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 27: 477-480
27. Senn HJ, Jungi WF, Amgwerd R, Hochuli E, Ammann J, Engelhart G, Heinz C, Wick A, Enderlin F, Creux G, Simeon B, Lanz R, Bigler R and Seiler S (1984) Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results. Recent Results Cancer Res 96: 90-101
28. SERC (1988) EGRET user's manual. Statistics and epidemiology research corporation: Seattle
29. Tancini G, Bonadonna G, Valagussa P, Marchini S and Veronesi U (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2-10
30. Tannock IF, Boyd NF, Deboer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D and Sutherland H (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387
31. Tormey D, Gelman R and Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. Am J Clin Oncol 6: 1-18
32. Velez-Garcia E, Carpenter JT, Moore M, Vogel CL, Marcial V, Ketcham A, Raney M and Smalley R (1987) Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: progress report of a Southeastern Cancer Study Group (SEG) trial. Adjuvant Ther Cancer 5: 347-355
33. Walters RS, Frye D, Buzdar AU, Holmes FA and Hortobagyi GN (1992) A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 69: 476-481
34. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei III E and Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259
35. Yosef H, Slater A, Keen CW, Bunting JS, Hope-Stone H, Parmar, H, Roberts JT, Termander B and Nilsson B (1993) Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer 29(A): 1100-1105